Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

Articles published in Journal of Bioequivalence & Bioavailability have been cited by esteemed scholars and scientists all around the world. Journal of Bioequivalence & Bioavailability has got h-index 26, which means every article in Journal of Bioequivalence & Bioavailability has got 26 average citations.

Following are the list of articles that have cited the articles published in Journal of Bioequivalence & Bioavailability.

  2022 2021 2020 2019 2018

Year wise published articles

60 61 19 6 27

Year wise citations received

394 412 405 380 363
Journal total citations count 4363
Journal Impact Factor 6.89
Journal 5 years Impact Factor 11.60
Journal CiteScore 14.43
Journal h-index 26
Important citations

The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention

Fixed dose combination products as Oro-dispersible tablets: A review

Studying the Release Characteristics of Naproxen Sustained Release Matrix Tablet Using Natural Polyelectrolytes

The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries

How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries.

Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.

Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measu

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.

Aspirin resistance, the enemy of my friend is my enemy

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study

Aspirin resistance, the enemy of my friend is my enemy

Application of Design of Experiments® Approach-Driven Artificial Intelligence and Machine Learning for Systematic Optimization of Reverse Phase High Performance Liquid Chromatography Method to Analyze Simultaneously Two Drugs (Cyclosporin A and Etodolac) in Solution, Human Plasma, Nanocapsules, and Emulsions

Validation of routine analytical method for injectable cyclosporine preparation control using HPLC-FIA assay.

A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal Doxylamine in Subjects with Chronic Intermittent Sleep Impairment

Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia.